Clinical Trial

The Effects of Xuezhikang and Atorvastatin on Lipid in Patients With Dyslipidemia and Prediabetes

Study acronym: Xuezhikang
Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated April 3, 2025 (before its estimated March 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study compares the impact of Xuezhikang and atorvastatin on glucose metabolism to explore the incidence of prediabetes patients developing diabetes after 24 weeks of Xuezhikang use, and by investigating the effect of Xuezhikang on blood glucose fluctuations, discusses the possible mechanisms by which Xuezhikang affects glucose metabolism.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-12-20; most recent amendment 2025-04-01.
Trial Details
NCT Number NCT06750783
Lead Sponsor Beijing Tsinghua Chang Gung Hospital
Conditions Prediabetic State (IGT)
Enrollment 398 participants
Start Date 2024-12-31
Primary Completion 2026-03-31 (estimated)
Study Completion 2026-03-31 (estimated)
Updated on ClinicalTrials.gov 2025-04-03